Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Dennis Poel"'
Autor:
Ronja S. Adam, Dennis Poel, Leandro Ferreira Moreno, Joey M. A. Spronck, Tim R. deBack, Arezo Torang, Patricia M. Gomez Barila, Sanne tenHoorn, Florian Markowetz, Xin Wang, Henk M. W. Verheul, Tineke E. Buffart, Louis Vermeulen
Publikováno v:
Molecular Oncology, Vol 16, Iss 14, Pp 2693-2709 (2022)
Previously, colorectal cancer (CRC) has been classified into four distinct molecular subtypes based on transcriptome data. These consensus molecular subtypes (CMSs) have implications for our understanding of tumor heterogeneity and the prognosis of p
Externí odkaz:
https://doaj.org/article/67372eeed1f24b6089c25d30995100a1
Autor:
Beatriz Subtil, Kirti K. Iyer, Dennis Poel, Lotte Bakkerus, Mark A. J. Gorris, Jorge Cuenca Escalona, Koen van den Dries, Alessandra Cambi, Henk M. W. Verheul, I. Jolanda M. de Vries, Daniele V. F. Tauriello
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Colorectal cancer (CRC) remains one of the most aggressive and lethal cancers, with metastasis accounting for most deaths. As such, there is an unmet need for improved therapies for metastatic CRC (mCRC). Currently, the research focus is shifting tow
Externí odkaz:
https://doaj.org/article/85ec0e0b943e473fa55810e64ba562a6
Autor:
Dennis Poel, Elske C. Gootjes, Lotte Bakkerus, Wim Trypsteen, Henk Dekker, Hans J. van derVliet, Nicole C. T. vanGrieken, Cornelis Verhoef, Tineke E. Buffart, Henk M. W. Verheul
Publikováno v:
Cancer Medicine, Vol 9, Iss 20, Pp 7558-7571 (2020)
Abstract Background Palliative systemic therapy is currently standard of care for patients with extensive metastatic colorectal cancer (mCRC). A biomarker predicting chemotherapy benefit which prevents toxicity from ineffective treatment is urgently
Externí odkaz:
https://doaj.org/article/2ede2aac37804a52ab03c1a26358e7e8
Autor:
Sophie L. Gerritse, Mariette Labots, Rob ter Heine, Henk Dekker, Dennis Poel, Daniele V. F. Tauriello, Iris D. Nagtegaal, Erik Van Den Hombergh, Nielka Van Erp, Henk M. W. Verheul
Publikováno v:
Cancers, Vol 14, Iss 24, p 6061 (2022)
Patients with advanced cancer refractory to standard treatment were treated with sunitinib at a dose of 300 mg once every week (Q1W) or 700 mg once every two weeks (Q2W). Tumor, skin and plasma concentrations were measured and immunohistochemical sta
Externí odkaz:
https://doaj.org/article/14e864f443a7441685f675b52280d8cd
Autor:
Annette A. van Zweeden, Roza C.M. Opperman, Richard J. Honeywell, Godefridus J. Peters, Henk M.W. Verheul, Hans J. van der Vliet, Dennis Poel
Publikováno v:
Cancer Treatment and Research Communications, Vol 27, Iss , Pp 100371- (2021)
The prognosis of patients with advanced oesophageal cancer (EC) and gastric cancer (GC) is poor. Circulating microRNAs (ci-miRNAs) may have prognostic and predictive value to improve patient selection for palliative treatment. The purpose of this stu
Externí odkaz:
https://doaj.org/article/b255676a7ac243bd8be6dedf441bc7ad
Autor:
Maarten Neerincx, Dennis Poel, Daoud L S Sie, Nicole C T van Grieken, Ram C Shankaraiah, Floor S W van der Wolf-de Lijster, Jan-Hein T M van Waesberghe, Jan-Dirk Burggraaf, Paul P Eijk, Cornelis Verhoef, Bauke Ylstra, Gerrit A Meijer, Mark A van de Wiel, Tineke E Buffart, Henk M W Verheul
Publikováno v:
PLoS ONE, Vol 13, Iss 8, p e0201809 (2018)
BACKGROUND:First line chemotherapy is effective in 75 to 80% of patients with metastatic colorectal cancer (mCRC). We studied whether microRNA (miR) expression profiles can predict treatment outcome for first line fluoropyrimidine containing systemic
Externí odkaz:
https://doaj.org/article/565afe6c0e7f466f9639d433649f1fad
Autor:
Dennis Poel, Lenka N.C. Boyd, Robin Beekhof, Tim Schelfhorst, Thang V. Pham, Sander R. Piersma, Jaco C. Knol, Connie R. Jimenez, Henk M.W. Verheul, Tineke E. Buffart
Publikováno v:
Cells, Vol 8, Iss 9, p 1111 (2019)
Most patients with advanced colorectal cancer (CRC) eventually develop resistance to systemic combination therapy. miR-195-5p and miR-497-5p are downregulated in CRC tissues and associated with drug resistance. Sensitization to 5-FU, oxaliplatin, and
Externí odkaz:
https://doaj.org/article/b04312636a034cdc827e41293782ba9c
Autor:
Kirti Krishnamurthy Iyer, Dennis Poel, Anne Miggelenbrink, Wouter Kerkhof, Jorien Janssen, Lotte Bakkerus, Loek de Jong, Erik van den Hombergh, Iris D. Nagtegaal, Daniele V.F. Tauriello, Nielka van Erp, Henk M.W Verheul
Background Despite major interest in tyrosine kinase inhibitors (TKIs) as a treatment option for metastatic colorectal cancer (mCRC), almost all TKIs tested for mCRC fail in early-phase clinical trials. Although showing specific target inhibition at
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::07d186b3ac04e31a8aa518385714a7f3
https://doi.org/10.21203/rs.3.rs-2867114/v1
https://doi.org/10.21203/rs.3.rs-2867114/v1
Autor:
Dennis Poel, Kirti K. Iyer, Bob van Gasteren, Beau Dagniaux, Erik van den Hombergh, Nielka P. van Erp, Daniele V. Tauriello, Henk M. Verheul
Publikováno v:
Cancer Research. 83:418-418
For unresectable metastatic colorectal cancer (mCRC), the main treatment strategy is combination chemotherapy, targeted therapy, or immunotherapy. Long-term treatment benefit of these therapies is limited to a small subgroup of patients. To improve t
Autor:
Kirti K. Iyer, Dennis Poel, Anne Miggelenbrink, Wouter Kerkhof, Erik van den Hombergh, Loek A. de Jong, Nielka P. van Erp, Daniele V. Tauriello, Henk M. Verheul
Publikováno v:
Cancer Research. 83:4028-4028
Despite major interest in tyrosine kinase inhibitors (TKIs) as a treatment option for metastatic colorectal cancer (mCRC), almost all TKIs tested for mCRC fail in early-phase clinical trials. Although showing specific target inhibition at low concent